Mechanism-based inhibition of human Cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content

Xenobiotica

Volumn 42, Issue 12, 2012, Pages 1163-1169

  Greenblatt, David J ^a   Zhao, Yanli ^a   Hanley, Michael J ^a   Chen, Chunxian ^b   Harmatz, Jerold S ^a   Cancalon, Paul F ^c   Gmitter, Frederick G ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Florida Department of Citrus   (United States)

Author keywords

Cytochrome P450 3A; Drug interactions; Furanocoumarin; Grapefruit juice

Indexed keywords

6', 7' DIHYDROXYBERGAMOTTIN; BERGAMOTTIN; CYTOCHROME P450; FUROCOUMARIN; ISOIMPERATORIN; KETOCONAZOLE; TRIAZOLAM; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GRAPEFRUIT JUICE; HUMAN; HUMAN TISSUE; HYDROXYLATION; IC 50; IN VITRO STUDY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MINIMUM INHIBITORY CONCENTRATION; SUICIDE SUBSTRATE;

EID: 84868614179     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.700428     Document Type: Article

References (33)

1. Bailey DG, Arnold JMO, Spence JD. (1998). Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110.
2. Cancalon PF, Barros SM, Haun C, Widmer WW. (2011). Effect of maturity, processing, and storage on the furanocoumarin composition of grapefruit and grapefruit juice. J Food Sci 76:C543-C548.
3. Chen C, Cancalon P, Haun C, Gmitter F. (2011). Characterization of furanocoumarin profile and inheritance toward selection of low furanocoumarin seedless grapefruit cultivars. J Am Soc Hortic Sci 136:358-363.
4. De Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, Derendorf H. (2006). Variation of flavonoids and furanocoumarins in grapefruit juices: A potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem 54:249-255.
5. Farkas D, Greenblatt DJ. (2008). Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 4:381-393.
6. Fontana E, Dansette PM, Poli SM. (2005). Cytochrome p450 enzymes mechanism based inhibitors: Common sub-structures and reactivity. Curr Drug Metab 6:413-454.
7. Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. (1997). Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 7:391-396.
8. Greenblatt DJ. (2010). Update on drug interactions with grapefruit juice: An evidence-based review. Pharmacy Times 76 (Jan):95-104.
9. Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH, von Moltke LL. (2011). Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol 63:214-221.
10. Greenblatt DJ, Venkatakrishnan K, Harmatz JS, Parent SJ, von Moltke LL. (2010). Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro. Xenobiotica 40:713-720.
11. Guo LQ, Taniguchi M, Xiao YQ, Baba K, Ohta T, Yamazoe Y. (2000a). Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn J Pharmacol 82:122-129.
12. Guo LQ, Fukuda K, Ohta T, Yamazoe Y. (2000b). Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 28:766-771.
13. Guo LQ, Yamazoe Y. (2004). Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin 25:129-136.
14. Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. (2011). The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 7:267-286.
15. Hanley MJ, Cerundolo R, Radwanski N, Court MH. (2010). Grapefruit juice, lyophilized grapefruit juice, and powdered whole grapefruit inhibit cytochrome P450-mediated triazolam hydroxylation by beagle dog liver microsomes. J Vet Pharmacol Ther 33:189-195.
16. Mertens-Talcott SU, Zadezensky I, De Castro WV, Derendorf H, Butterweck V. (2006). Grapefruit-drug interactions: Can interactions with drugs be avoided? J Clin Pharmacol 46:1390-1416.
17. Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanismbased inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
18. Ohta T, Maruyama T, Nagahashi M, Miyamoto Y, Hosoi S, Kiuchi F, Yamazoe Y, Tsukamoto S. (2002). Paradisin C: A new CYP3A4 inhibitor from grapefruit juice. Tetrahedron 58:6631-6635.
19. Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF, Watkins PB. (2006). A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 83:1097-1105.
20. Paine MF, Widmer WW, Pusek SN, Beavers KL, Criss AB, Snyder J, Watkins PB. (2008). Further characterization of a furanocoumarinfree grapefruit juice on drug disposition: Studies with cyclosporine. Am J Clin Nutr 87:863-871.
21. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ. (2000). Midazolam and triazolam biotransformation in mouse and human liver microsomes: Relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618-628.
22. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL. (2005). Atazanavir: Effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33:764-770.
23. Silverman RB. (1995). Mechanism-based enzyme inactivators. Meth Enzymol 249:240-283.
24. Uesawa Y, Mohri K. (2006a). The use of heat treatment to eliminate drug interactions due to grapefruit juice. Biol Pharm Bull 29:2274-2278.
25. Uesawa Y, Mohri K. (2006b). UV-irradiated grapefruit juice loses pharmacokinetic interaction with nifedipine in rats. Biol Pharm Bull 29:1286-1289.
26. Uesawa Y, Abe M, Fukuda E, Baba M, Okada Y, Mohri K. (2011). Construction of a model to estimate the CYP3A inhibitory effect of grapefruit juice. Pharmazie 66:525-528.
27. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (2000). Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Clin Pharmacokinet 38:111-180.
28. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. (1996). Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
29. Widmer W, Haun C. (2005). Variation in furanocoumarin content and new furanocoumarin dimers in commerical grapefruit (Citrus paradisi Macf.) juices. J Food Sci 70:c307-c312.
30. Yu J, Buslig BS, Haun C, Cancalon P. (2009). New furanocoumarins detected from grapefruit juice retentate. Nat Prod Res 23:498-506.
31. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304.
32. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. (2007). Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687-710.
33. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A. (2004). Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415-442.